Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00446186 |
The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.
Condition | Intervention | Phase |
---|---|---|
Rhinitis Allergic |
Drug: MK0476, montelukast sodium / Duration of Treatment: 2 Weeks Drug: Comparator: placebo / Duration of Treatment: 2 Weeks |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Mk0476 Phase II Dose Finding Study -Allergic Rhinitis- |
Ages Eligible for Study: | 15 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_009 |
Study First Received: | March 9, 2007 |
Last Updated: | March 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00446186 History of Changes |
Health Authority: | Japan: Pharmaceuticals and Medical Devices Agency |
Montelukast Signs and Symptoms Otorhinolaryngologic Diseases Respiratory Tract Infections Respiratory Tract Diseases Hormone Antagonists |
Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Rhinitis Hormones Leukotriene Antagonists |
Respiratory System Agents Otorhinolaryngologic Diseases Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Rhinitis |
Nose Diseases Pharmacologic Actions Leukotriene Antagonists Montelukast Respiratory Tract Diseases Respiratory Tract Infections Therapeutic Uses |